Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, can prove challenging to address in real-world settings. Although biologics directed against TNF-α can rapidly and sustainably induce clinical remission of these conditions, they have incomplete efficacy; many other conventional treatments used alongside biologics additionally have complex safety profiles that limit their use. These limitations have spurred the development and examination of novel agents, such as Janus Kinase (JAK) inhibitors, in patients with inadequately controlled disease. Through this three-part, small-group educational program, rheumatologists and other supporting healthcare providers can gain greater familiarity with the mechanisms of action behind different JAK inhibitors, evaluate their efficacy and safety in different patient populations, and become acquainted with strategies to improve access to these agents on behalf of their patients. In doing so, clinicians can ensure that the next generation of therapies for immune-mediated inflammatory diseases are used to their fullest potential.

CME/CE Accreditation Information